Physician profile
Amber Dawson
NPI 1689018665
$2,366.74
in general payments reported to CMS, 2019-2025
21 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $241 · 2023: $752 · 2024: $524 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.75 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $415.70 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Dexcom, INC. | $257.68 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $192.53 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $141.05 | 2021-2024 | Evenity, Prolia |
| Lilly USA, LLC | $140.36 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Genzyme Corporation | $106.48 | 2023 | |
| Exact Sciences Corporation | $100.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $80.81 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $64.98 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $63.80 | 2025 | Ibsrela |
| Medtronic, INC. | $46.50 | 2024 | Minimed 780g |
| Insulet Corporation | $35.01 | 2022-2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $32.84 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.65 | 2025 | Caplyta |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.35 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.19 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $18.18 | 2023 | |
| Biogen, INC. | $17.92 | 2025 | Skyclarys |
| Abbott Laboratories | $15.34 | 2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.